Arecor Therapeutics’ subsidiary Tetris Pharma has announced a commercialisation agreement with Goodlife for Ogluo.

Under the exclusive agreement, Goodlife will act as sole partner to import, market and distribute Ogluo in the BeNeLux region.

Ogluo is a ready-to-use, ambiently stored glucagon preparation in an auto-injector for patients in the licensed indication with diabetes and severe hypoglycaemia.

The National Healthcare Institute of the Netherlands, Zorginstiuut Nederland, granted approval for Ogluo at the requested price on List 1B.

Goodlife is expected to launch Ogluo in the country during the first half of next year.

Arecor CEO Sarah Howell said: “Goodlife provides the commercial expertise and detailed understanding of regional market dynamics that are essential for the company’s continued rollout of Ogluo and its market adoption in the Benelux region.

“The upcoming launch in the Netherlands adds to existing markets in the UK, Germany, Austria, Denmark and Norway, as part of the planned ongoing pan-European commercial rollout for this important product.”

Ogluo received marketing authorisation from the European Commission in February 2021.

Hypoglycaemia, which is characterised by abnormally low levels of blood sugar, is a serious complication of diabetes and affects individuals with diabetes on insulin treatment, in particular.

Goodlife managing director Koen Perenboom said: “With more than a quarter of a million people living with insulin-treated diabetes and at risk of severe hypoglycaemia in the Netherlands, Ogluo is an important treatment option for people with diabetes and their caregivers that can provide them with the confidence to manage severe hypoglycaemic events.”